This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical (FMS) gains from solid international revenues in Q1.
HMS Holdings' (HMSY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Top-line growth, higher commercial and state government revenues and expansion in margins aid HMS Holdings (HMSY) in Q1 earnings. However, increase in cost of services remains a woe.
Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Top-line growth and better performance at Medical and Non-Medical segments benefit Integer Holdings' (ITGR) Q1 results. However, contraction in gross margin remains a dampener.
AMN Healthcare (AMN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Higher revenues and expansion in gross margin find reflection in AMN Healthcare's (AMN) Q1 results. However, weak performance at Nurse and Allied and Locum Tenens segments remain woes.
Globus Medical (GMED) Q1 Earnings Miss, Revenues Grow Y/Y (Revised)
by Zacks Equity Research
Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) Q1 earnings gain from Technology & Equipment unit despite international revenues being down.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q1
by Zacks Equity Research
Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.
Medidata (MDSO) Q1 Earnings Beat Estimates, Margins fall
by Zacks Equity Research
Medidata (MDSO) witnesses year-over-year revenue growth in double-digits across both operating segments in first-quarter 2019.
PRA Health (PRAH) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
PRA Health's (PRAH) Q1 earnings reflect top-line growth, favorable segmental performance and margin expansion.
Globus Medical (GMED) Q1 Earnings Miss Mark, Margins Weak
by Zacks Equity Research
Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.
ResMed's (RMD) Q3 Earnings Beat Estimates, Revenues in Line
by Zacks Equity Research
ResMed (RMD) registers double-digit global revenue growth in Q3 on the back of solid sales from Software-as-a-Service businesses and new mask products plus devices.
Teleflex (TFX) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Teleflex (TFX) reports robust improvement in revenues on balanced growth across all segments and geographies.
Cardiovascular Systems (CSII) Q3 Earnings Top, View Tapered
by Zacks Equity Research
Cardiovascular Systems (CSII) rides high on a year-over-year rise in both Coronary and peripheral device revenues.
NuVasive (NUVA) Q1 Earnings Top Estimates, Margins Strong
by Zacks Equity Research
NuVasive's (NUVA) solid international sales in Q1 boost investor confidence in the stock.
DexCom (DXCM) Beats on Q1 Earnings, Hikes '19 Guidance
by Zacks Equity Research
DexCom's (DXCM) Q1 earnings gain from top-line growth and solid segmental performance. However, contraction in gross margin remains a headwind.
AmerisourceBergen (ABC) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
AmerisourceBergen's (ABC) Q2 earnings gain from solid segmental performance and higher adjusted operating income growth. But contraction in adjusted gross and operating margins remains a dampener.
Amedisys (AMED) Tops Earnings and Revenue Estimates in Q1
by Zacks Equity Research
At Home Health and Hospice divisions, Amedisys (AMED) witnesses solid year-over-year growth in Medicare and non-Medicare revenues.
ABIOMED (ABMD) Q4 Earnings Meet Estimates, Sales Rise in Japan
by Zacks Equity Research
ABIOMED's (ABMD) Q4 results gain from solid Impella show in Japan.
Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Hologic (HOLX) registers solid Q1year-over-year revenue growth in core businesses like Breast Health and Molecular Diagnostics.
CVS Health's (CVS) Q1 Earnings Top Estimates, EPS View Up
by Zacks Equity Research
Year-over-year growth in CVS Health's (CVS) top line is aided by a strong Pharmacy Services segment, benefiting from the upside in specialty services.
IDEXX (IDXX) Q1 Earnings Top Estimates, EPS Guidance Up
by Zacks Equity Research
Strong sales at the CAG business favor IDEXX's (IDXX) top line in Q1.
Tandem's (TNDM) Q1 Loss Wider Than Expected, Sales Top Mark
by Zacks Equity Research
Tandem's (TNDM) introduction of t:slim X2 with Basal-IQ technology, ramped-up supply capacity along with its global launch, substantially drive its top line in Q1.
LabCorp (LH) Q1 Earnings Top Mark, Revenues Lag Estimates
by Urmimala Biswas
Despite increasing acquisitions and favorable mix, the disposition of certain businesses and the implementation of PAMA are adversely affecting LabCorp's (LH) growth.
Chemed (CHE) Q1 Earnings Miss Estimates, Revenues Grow Y/Y
by Zacks Equity Research
Despite several downsides, Chemed (CHE) witnesses solid revenue growth across key subsidiaries - VITAS and Roto-Rooter.